Company intelligence / Profile preview

EpiBiome

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

EpiBiome developed a first-in-class automated phage discovery platform rapidly creating phage cocktails for pathogens with unmet medical need, notably targeting antibiotic-resistant bacteria. The platform enabled development acceleration and formation of cocktails to address significant clinical and agricultural needs. Assets and IP were acquired by Locus Biosciences in 2018 to enhance their CRISPR-Cas3 bacteriophage therapeutic pipeline and advance several programs, including those for major nosocomial infections and microbiome-associated diseases[1][2].

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Partnerships

Johnson & Johnson Innovation (JLABS program)Illumina Accelerator

Beyond the preview

Go deeper on EpiBiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiBiome.

Explore the full profile